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Curcumin mediates oxaliplatin-
acquired resistance reversion in 
colorectal cancer cell lines through 
modulation of CXC-Chemokine/
NF-κB signalling pathway
Vicenç Ruiz de Porras1,7, Sara Bystrup1,7, Anna Martínez-Cardús2, Raquel Pluvinet3, 
Lauro Sumoy3, Lynne Howells4, Mark I. James4, Chinenye Iwuji4, José Luis Manzano1,5,7, 
Laura Layos1,5,7, Cristina Bugés1,5,7, Albert Abad6 & Eva Martínez-Balibrea1,7
Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal 
cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling pathway has been 
proposed as an important mechanism involved in this phenomenon. Here, we show that NF-κB was 
hyperactivated in in vitro models of OXA-acquired resistance but was attenuated by the addition of 
Curcumin, a non-toxic NF-κB inhibitor. The concomitant combination of Curcumin + OXA was more 
effective and synergistic in cell lines with acquired resistance to OXA, leading to the reversion of their 
resistant phenotype, through the inhibition of the NF-κB signalling cascade. Transcriptomic profiling 
revealed the up-regulation of three NF-κB-regulated CXC-chemokines, CXCL8, CXCL1 and CXCL2, 
in the resistant cells that were more efficiently down-regulated after OXA + Curcumin treatment as 
compared to the sensitive cells. Moreover, CXCL8 and CXCL1 gene silencing made resistant cells more 
sensitive to OXA through the inhibition of the Akt/NF-κB pathway. High expression of CXCL1 in FFPE 
samples from explant cultures of CRC patients-derived liver metastases was associated with response to 
OXA + Curcumin. In conclusion, we suggest that combination of OXA + Curcumin could be an effective 
treatment, for which CXCL1 could be used as a predictive marker, in CRC patients.
Colorectal Cancer (CRC) is still one of the most frequent causes of cancer-related death worldwide. The 5-year 
overall survival rate is less than 10% in advanced disease and chemotherapy treatment remains essential for these 
patients. Thus, despite the availability of targeted therapies against the Epidermal Growth Factor Receptor (EGFR) 
or the Vascular Endothelial Growth Factor (VEGF), combinations of oxaliplatin (OXA) with fluoropyrimidines 
(5-fluorouracil or capecitabine) are the most commonly used frontline regimens in the metastatic disease1. OXA 
is a third-generation platinum drug and it is the only platinum analogue that has activity in CRC, in both adju-
vant and first-line treatment2. OXA cytotoxicity is mainly generated through the formation of platinum-DNA 
adducts resulting in DNA transcription and replication blockade. As a consequence, several signalling pathways 
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are activated leading to DNA damage repair and/or the activation of cell death programs3. However, as with other 
chemotherapies, its effectiveness is limited by the appearance of drug resistance4. Chemoresistance associated 
with OXA is a complex and multifactorial process in which several mechanisms such as drug influx/efflux modi-
fications, alterations in DNA damage repair, decrease of cell death activation, autocrine survival signalling or high 
detoxification activity could play a part5. Amongst these processes, the Nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κ B) has been implicated in the activation of survival pathways following OXA treat-
ment, and may be an important factor in mediating acquired resistance to OXA. NF-κ B is a transcription 
factor that contributes to the progression of CRC by regulating the expression of diverse target genes that are 
involved in inflammation (e.g. TNFα , IL-1, CXC-chemokines), cell proliferation (e.g. Cyclin D1, COX2, c-myc, 
IL-6), apoptosis (e.g. XIAP, IAP-1, IAP-2, Survivin, Bcl-2 and Bcl-xl), angiogenesis (e.g. VEGF, IL-8), invasion 
(e.g. ICAM-1, VCAM-1) and metastasis (e.g. MMP-9)6. Constitutive activation of NF-κ B has been observed in 
many solid tumours, including CRC7,8, and provides a survival mechanism by up-regulating anti-apoptotic genes 
and thereby representing a major causative factor for drug resistance9. Of note, it has been shown that administra-
tion of OXA can potentiate NF-κ B activity, increasing transcriptional regulation and expression of anti-apoptotic 
genes10. Thus, the inhibition or modulation of NF-κ B and its downstream targets has been proposed as an impor-
tant target for the development of therapeutic approaches against this disease and the resistance to platinum 
agents11. In previous work, we investigated the alteration in gene transcription patterns between sensitive and 
OXA-acquired resistant human CRC cell lines. Our results led us to hypothesize that the NF-κ B signalling path-
way was an important contributor in the development of OXA resistance in this model12 and that a reasonable 
strategy for CRC cancer treatment may be the combination of OXA-based chemotherapy with compounds active 
against NF-κ B. One such compound is Curcumin (diferuloylmethane), the major active ingredient of turmeric 
(Curcuma longa). Curcumin, with no discernable toxicity, inhibits the growth of transformed cells13,14 and also 
has been shown to suppress initiation, promotion, and progression of colon carcinogenesis in induced rodent 
models15. In the past few years, several studies have demonstrated that Curcumin inhibits NF-κ B activity and 
down-regulates the expression of NF-κ B regulated gene products in different cell types at nontoxic concentra-
tions in humans, leading to the suppression of proliferation, cell cycle arrest and induction of apoptosis16,17. It has 
also been reported that Curcumin enhances the effect of diverse anti-cancer drugs against CRC, including OXA 
and 5- fluorouracil, both in in vitro and in vivo models18–23. The anti-tumour activity and safety of Curcumin has 
been extensively studied in humans, and several clinical trials are on-going in order to evaluate new formulations 
with greater bioavailability and combinations with conventional chemotherapy24–26. Despite its poor systemic bio-
availability, Curcumin has been reported to distribute in gastrointestinal tract to a great extent and is independent 
of systemic availability, demonstrating the potential to prevent and reduce CRC27.
The aims of this work were firstly, to demonstrate that the NF-κ B pathway was hyper-activated in CRC cells 
with acquired resistance to OXA and to evaluate whether the combined treatment of Curcumin and OXA could 
revert this phenotype and secondly, to find one or more predictive markers for the effectiveness of this combina-
tion that could be used in the selection of patients with high probability to respond to this treatment.
Results
The NF-κB pathway is hyperactivated in CRC cell lines with acquired resistance to OXA. 
Previous results from our group suggested an important role for the NF-κ B pathway in OXA resistance acqui-
sition in in vitro models12. In the present work, we tried to demonstrate this hypothesis by first investigating the 
NF-κ B basal status in 3 CRC Cell lines (HT29, LoVo and DLD1) and their corresponding OXA-resistant derived 
sub-lines (HTOXAR3, LoVOXAR3 and DLDOXAR3, respectively). As shown in Fig. 1 all the cell lines had 
constitutively phosphorylated p65 subunit at Ser536 which is considered an indicator of this pathway’s activity9. 
However, we observed an increase in this phosphorylation in HTOXAR3 (Fig. 1a,b) and DLDOXAR3 (Fig. 1a,d) 
as compared with their parental cell lines. Besides this, increased levels of phosphorylated Iκ Bα at Ser32/36 
residues, indicating degradation of this NF-κ B inhibitor by the proteasome and p65 nuclear translocation, were 
also found in all three resistant cell lines in comparison with their respective parental ones. Taking into account 
that Survivin, Bcl-2 and Cyclin D1 have all been shown to be transcriptionally regulated by NF-κ B6, we exam-
ined the basal expression levels of these proteins by western blot. We observed that all of them were significantly 
overexpressed in HTOXAR3 as compared to HT29 cells (Fig. 1a,b). In the case of the LoVo/LoVOXAR3 pair we 
observed a significant increase in Bcl-2 and Cyclin D1 protein expression in the resistant cell line (Fig. 1a,c) while 
only Survivin protein expression showed statistically significant differences between DLDOXAR3 and DLD1 
(Fig. 1a,d). The Serine/threonine kinase Akt plays a critical role in proliferation and cell survival and its impli-
cation in the activation of anti-apoptotic mechanisms such as those driven by NF-κ B is well documented28,29. 
In agreement with this, in our previous study we reported increased levels of AKT1 mRNA in OXA-resistant 
cell lines12. Here we also demonstrate a significantly increased phosphorylation of Akt at Ser473 in HTOXAR3 
as compared to HT29 cells (Fig. 1a,b) suggesting a possible role for Akt in the NF-κ B pathway activation in the 
HTOXAR3 cell line.
Taken together, our results indicate that the NF-κ B pathway is hyper-activated as a result of OXA resist-
ance acquisition, especially in the HTOXAR3 resistant cell line. In addition, through immunocytochemistry 
experiments, we corroborated this finding since the HTOXAR3 cell line showed increased p65 nuclear staining 
compared to HT29 (Fig. 1e). Therefore, we used the HT29/HTOXAR3 pair as a model to perform most of the 
subsequent analysis.
OXA induces NF-κB activation in CRC cells. NF-κ B pathway could be activated through two mech-
anisms: signals that originate at cell receptors and signals that originate in the nucleus in response to DNA 
damage. Treatment with OXA potentiated NF-κ B activation in different cell types, including CRC cell lines10,30. 
Accordingly, we assessed the phosphorylation status of p65 and Iκ Bα , and the expression of three NF-κ B target 
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genes in HT29 and HTOXAR3 cell lines after short OXA-exposure times (0 to 120 min) and after 24 h of OXA 
treatment at 10 and 30 μM (IC50 values), respectively. We observed that OXA induced a fast phosphoryla-
tion of p65 and Iκ Bα after the first 15 min of treatment and potentiated the expression of Bcl-2, Survivin and 
Cyclin D1 in both cell lines. Despite a slightly decrease in the expression of these proteins was observed after 30’ 
post-treatment, higher levels as compared to non-treated cells were maintained until at least 120’ after OXA treat-
ment. Interestingly, we observed a trend to a more evident activation in HT29 as compared with HTOXAR3 cell 
line (Fig. 2a and Supplementary Fig. S1). In fact, these differences were more evident after a 24 h exposure since 
p65 and Iκ Bα phosphorylation and Bcl-2 and Survivin expression increased in HT29 but not in HTOXAR3 cell 
line in a statistically significant way. In contrast, Cyclin D1 protein levels decreased significantly in both cell lines, 
this effect being more evident in the parental cell line. As previously described in HT29 cells31 we did not observe 
a significant Iκ Bα protein degradation (Fig. 2b,c). When NF-κ B is activated, the p65 subunit translocates to the 
cell nucleus. To confirm that OXA treatment promotes p65 nuclear translocation, HT29 cells were treated with 
OXA (10 μM) for varying lengths of times, and p65 expression in nuclear and cytoplasmic extracts was analysed 
by western blot. Nuclear p65 increased as early as 15 min after OXA exposure (Fig. 2d) and was sustained at least 
after 24 h of OXA treatment (Fig. 2e). TNFα was used as a positive control due to its ability to activate the NF-κ B 
pathway.
Collectively, these results suggest that the combination of OXA with an NF-κ B inhibitor could be an appro-
priate strategy to revert OXA resistance in our in vitro model. We tried that our work was the most closed to 
the clinics as possible. More than 700 different inhibitors of NF-κ B have been reported, yet no blocker of this 
transcription factor has been approved for human use. We therefore selected the natural compound Curcumin 
(diferuloylmethane) in order to block NF-κ B activation in our cells due to its strong ability to inhibit this pathway 
and its low toxicity profile in humans as reported in several phase I and II clinical trials32–34.
Concomitant treatment OXA plus Curcumin for 24 hours reverts OXA resistance in CRC cells. A 
panel of 3 CRC cell lines and their respective OXA-resistant cells were treated with increasing concentrations of 
Figure 1. NF-κB pathway activation in CRC cell lines with acquired resistance to OXA. Western blot 
analysis (a) and graphic representation of phosphorylated p65 (p-p65 Ser536, grey bars), phosphorylated Iκ Bα 
(p-Iκ Bα Ser32/36, red bars), Survivin (orange bars), Bcl-2 (blue bars), Cyclin D1 (green bars), phosphorylated 
Akt (p-Akt Ser473, purple bars) and Iκ Bα (black bars) basal expression in HT29/HTOXAR3 (b), LoVo/
LoVOXAR3 (c) and DLD1/DLDOXAR3 (d) cell lines. Alpha-tubulin was used as endogenous control. 
(e) Representative immunocytochemistry images of the subcellular localization of p65 (red) in HT29 and 
HTOXAR3 cells. Nuclei were stained in blue. Objective lens: 40x immersion oil. Scale bar: 10 μm. Bar graphs 
represent mean ± SEM values, calculated from at least three independent experiments. *p-value < 0.05 and 
**p-value < 0.01; relative to protein expression in the corresponding sensitive cell line.
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Figure 2. Effect of OXA treatment on NF-κB activation in HT29 and HTOXAR3 cells. Representative 
western blot images showing protein expression changes of phosphorylated p65 (p-p65 Ser536), 
phosphorylated Iκ Bα (p-Iκ Bα Ser32/36), Survivin, Bcl-2 and Cyclin D1 in HT29 and HTOXAR3 cells after 
treatment with 10 μM or 30 μM of OXA respectively, for 0 to 120 minutes (a) and for 24 hours (b,c) Bar graphs 
representing mean ± SEM expression changes of the indicated proteins after a 24-hour OXA treatment with the 
corresponding IC50 dose for HT29 (10 μM) and HTOXAR3 (30 μM). Alpha-tubulin was used as endogenous 
control. (d) Western blots showing p65 protein expression in cytoplasmic and nuclear extracts of HT29 cells 
after OXA treatment at short exposure times (0 to 60 min) and at 24 hours (e). TNFα was used as positive 
control at 50 ng/mL. Msh2 and α -tubulin were used as nuclear- and cytoplasmic-specific protein controls, 
respectively. NT: Non-treated cells. Results shown were obtained from at least 3 independent experiments. 
*p-value < 0.05 and **p-value < 0.01; as compared to NT. #p-value < 0.05 relative to protein expression in the 
HT29 cell line.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:24675 | DOI: 10.1038/srep24675
Curcumin for 24 h. Curcumin decreased cell proliferation of all cell lines in a dose-dependent manner (IC50 
range 9.5–14.6 μM). Importantly, HTOXAR3 and LoVOXAR3 (Supplementary Fig. S2a,b) cells were more resist-
ant to Curcumin treatment as compared with HT29 and LoVo cell lines whereas DLDOXAR3 cells were more 
sensitive than their parental sensitive cell line, DLD1 (Supplementary Fig. S2c). Next we wanted to determine the 
most synergistic combination between OXA and Curcumin. To do that, HTOXAR3 resistant cells were treated 
with different combination schedules, with the most synergistic being the concomitant treatment of both drugs 
for 24 h, where the CI was <1 from IC40 onwards, CI = 1 at IC30 and was slightly higher than 1 at very low 
doses (IC10 and 20) (Fig. 3a). Therefore, we decided to use this combination in order to evaluate the effect of 
Curcumin on the reversion of OXA-acquired resistance in our models. We observed that this schedule signifi-
cantly decreased cell proliferation of both HT29 and HTOXAR3 cell lines (Fig. 3b,c) as compared with individual 
treatments. Remarkably, this reduction of cell viability was more evident in the HTOXAR3 cell line where in fact 
the combined treatment was able to revert the OXA-acquired resistance phenotype leading to a 65% reduction 
in the OXA IC50 (10.6 ± 2.2 μM with the combination vs. 30.2 ± 4.2 μM in individual treatment) and brought it 
closer to that of the HT29 sensitive cell line (8.45 ± 1.6 μM) (Fig. 3d). While in the HT29 cell line, the combina-
tion of Curcumin plus OXA was additive at the IC50 of these drugs and synergistic at doses higher than the IC50, 
in the resistant HTOXAR3 cells, the treatment started to be synergistic at the IC50 (Fig. 3e). Clonogenic assays 
revealed that while both drugs reduced the number of colonies as compared with untreated cells, their combina-
tion led to a complete absence of colonies in both HT29 and HTOXAR3 cells (Fig. 3f). In order to determine if 
these results could be explained by an increased cell death after the combined treatment, HT29 and HTOXAR3 
cells were treated with OXA, Curcumin or their combination at their respective IC50 doses for 24, 48 and 72 h. 
As can be seen in Fig. 3g, OXA induced cell death rates below 25% after 72 h of treatment in both cell lines while 
in the case of Curcumin alone these rates were less than 10% in all cases. However the percentage of dead cells 
was increased after treatment with OXA plus Curcumin for 72 h in HT29 cells and for 48 and 72 h in HTOXAR3 
only as compared with Curcumin alone. Similar results were obtained in the LoVo/LoVOXAR3 pair although an 
additive effect was observed only at high doses (IC90) of the two drugs in both cell lines (Supplementary Fig. S3).
In summary, these results suggest that the addition of Curcumin to OXA treatment sensitizes CRC cells to the 
latter, with this effect more evident in the OXA-resistant cell lines.
Curcumin inhibits the OXA-induced activation of NF-κB and decreases the expression of NF-κB 
anti-apoptotic and pro-proliferative gene products. In view of our results, we wanted to study the 
effect of the addition of Curcumin on OXA treatment at the molecular level. We first investigated the effect of 
Curcumin as a single agent on NF-κ B inhibition. HT29 and HTOXAR3 cells were treated with Curcumin at 
10 and 20 μM for 24 h. As expected, Curcumin decreased p65 phosphorylation and Survivin expression in a 
dose-dependent manner in both cell lines (Fig. 4a). Next, both cell lines were treated with OXA and OXA plus 
Curcumin at IC50 doses for short exposure times (0 to 120 min) and for 24 h. Results in Fig. 4b show that, in 
HT29/HTOXAR3 cells, the addition of Curcumin significantly decreased the OXA-induced phosphorylation 
of p65 (p < 0.001/p = 0.04) and Iκ Bα (p < 0.05/p = 0.02) as well as the expression of Bcl-2 (p < 0.03/p < 0.01), 
Survivin (p < 0.001/p = 0.02) and Cyclin D1 (p < 0.001/p = 0.04) after short treatment times. Similar results were 
observed after a 24 h-treatment, although they did not reach statistical significance (Fig. 4c). We also studied how 
the addition of Curcumin affected the OXA-induced p65 nuclear translocation. As shown in Fig. 4d,e, levels of 
nuclear p65 were decreased in all cases when HT29 cells were treated with OXA plus Curcumin as compared with 
OXA alone.
These results suggest that at least in part, the effects of Curcumin alone and in combination with OXA may be 
mediated by the inhibition of the NF-κ B signalling cascade.
Treatment with Curcumin and OXA induces different gene expression patterns between 
OXA-sensitive and -resistant cell lines. Our results indicate that the combination of Curcumin and 
OXA is more effective and synergistic in HTOXAR3 cell line, in which the NF-κ B pathway is hyper-activated, 
as compared with its sensitive-parental cell line, HT29. Given that NF-κ B is a transcription factor, we wanted 
to investigate whether a specific transcriptomic pattern was associated with this differential effect. Total RNA 
from HT29 and HTOXAR3 cells was obtained after vehicle treatment and after a 24 h-treatment with OXA or 
OXA plus Curcumin at IC50 doses and global transcriptional profiling was assessed using microarrays. We were 
interested in genes that were altered as a consequence of the resistance acquisition process and at the same time, 
were differentially expressed after treatment with the combined treatment. At the significance cut-off thresholds 
(|FC| > 1.2 and q-value < 0.05) the results showed 4,237 regulated transcripts when comparing the two cell lines 
under basal conditions (among 36,204 genes including unique gene symbols and other transcripts). A total of 
2,303 transcripts were up-regulated and 2,034 down-regulated in HTOXAR3 relative to HT29, confirming the 
involvement of multiple genes and pathways in OXA acquired resistance. There were 656 differentially regulated 
transcripts in the differential response analysis to combination treatment, 261 ‘up’ and 395 ‘down’ in HTOXAR3 
relative to HT29 (Supplementary Table S2).
The intersection between both lists allowed us to identify 75 genes up-regulated by the combination treatment 
in HTOXAR3 relative to HT29 which were repressed under basal conditions, and 194 genes showing the opposite 
relationship (activated under basal conditions in HTOXAR3 cells and down-regulated by combination treatment 
in these cells than in the sensitive parental cell line, HT29) (Supplementary Figure S4). Exploratory functional 
enrichment analysis revealed the biological processes induced by the combination treatment (with GSEA over-
lap q-values < 0.00001): interferon gamma response, complement, epithelial to mesenchymal transition (EMT) 
and TNFα signalling via NF-κ B in the 194 gene list and the TNFα signalling via NF-κ B in the 75 gene list 
(Supplementary Table S3). This is in agreement with the central role of the NF-κ B pathway in our OXA resistance 
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acquisition model and supports the coherence of our dataset with prior evidence. In addition it would support the 
proposed mechanism of action by Curcumin acting through the same pathway.
Figure 3. Combination of OXA and Curcumin in OXA-sensitive and –resistant CRC cell lines. (a) Graphic 
representation of the Combination Index (CI) values corresponding to different OXA plus Curcumin (CURC) 
treatment schedules in the HTOXAR3 cell line. (b) Bar graphs representing mean ± SEM percentage of cell 
viability after a 24-hour treatment with OXA, Curcumin or their concomitant combination at the indicated 
doses in HT29 and HTOXAR3 cells (c). *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001 relative to 
the indicated treatment condition. (d) OXA doses (mean ± SEM) corresponding to indicated inhibitory 
concentrations (IC) in HT29 and HTOXAR3 cells as a single agent or when combined with Curcumin 
concomitantly for 24 h. (e) OXA and Curcumin doses (mean ± SD) corresponding to the indicated inhibitory 
concentrations (IC) when given as single agents or in a 24 h-concomitant schedule in HT29 and HTOXAR3. CI 
represents the combination index values in each case. Synergistic values (CI < 1) are highlighted in green.  
(f) Bar graph representing the percentage (mean ± SEM) of colonies in HT29 and HTOXAR3 cells after 24 h 
of the indicated treatments. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001 relative to NT (Non-treated 
cells). #p-value < 0.05 relative to OXA individual treatment. ◆p-value < 0.05 as compared to HT29. (g) Bar graph 
representing the percentage (mean ± SEM) of dead cells after 24, 48 and 72 h of treatment with OXA, Curcumin 
or their combination (as compared to non-treated controls) at their corresponding IC50 doses in HT29 and 
HTOXAR3 cell lines. *p-value < 0.05; **p-value < 0.01, relative to NT. #p-value < 0,05, relative to Curcumin 
individual treatment.
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Among the top 10 genes fitting these criteria (Fig.  5) we observed that three pro-inflammatory 
CXC-chemokines, CXCL8 (Interleukin-8), CXCL1 (Gro-α ) and CXCL2 (Gro-β ) that are primarily regulated by 
NF-κ B35 were significantly up-regulated at basal level, and were more efficiently down-regulated after treatment 
with OXA plus Curcumin in the resistant cell line. Accordingly, functional enrichment analysis revealed cytokine 
signalling as one of the two molecular functions significantly overrepresented in this condition (Supplementary 
Figure S5). These results were validated through qRT-PCR experiments, confirming a basal overexpression of 
CXCL8 (~10-fold), CXCL1 (~ 6-fold) and CXCL2 (~2.5-fold) in HTOXAR3 cell line as compared with HT29 
(Fig. 6a). The three chemokines were up-regulated after OXA treatment only in HT29 cells (CXCL8 3-fold, 
CXCL1 6-fold and CXCL2 2-fold; Fig. 6a). In the case of CXCL2, we observed a down-regulation in expres-
sion after OXA treatment in HTOXAR3 cells. Interestingly, the OXA-induced expression of CXCL8 and CXCL1 
was significantly attenuated by the addition of Curcumin in the resistant cell line but not in the sensitive one 
(Fig. 6a). Down-regulation of CXCL2 with regards to basal conditions was also observed in the HTOXAR3 cell 
line after concomitant treatment (Fig. 6a). In view of these results, we investigated the effect of a 24 h-treatment 
with Curcumin as a single agent at different doses, on the expression of CXCL8 and CXCL1 observing a significant 
reduction in a dose-dependent manner only in the resistant cell line while in HT29 cells, this reduction was only 
observed at very high doses (Fig. 6b). ELISA-based analysis of HT29 and HTOXAR3 conditioned media revealed 
similar results at protein-secreted levels (Fig. 6c).
CXCL8 and CXCL1 siRNA-mediated gene silencing sensitizes HTOXAR3 resistant cells through 
the inhibition of the NF-κB signalling pathway. To confirm the specific role of CXCL8 and CXCL1 on 
OXA resistance acquisition in HTOXAR3 cells, we transiently silenced their gene expression by using siRNA oli-
gonucleotides. We assessed the cytotoxicity of OXA by MTT assay in control cells (siNTC) and CXCL8 or CXCL1 
knockdown cells (siCXCL8 or siCXCL1, respectively). Forty-eight hours after gene silencing, cells were seeded 
in 96-well plates and treated for 24 h with doses of OXA ranging 0–100 μM. CXCL8 and CXCL1 knockdown effi-
ciency was ~ 90% and ~60% at mRNA level, respectively (insets on Fig. 7a,b). Under these conditions, we found 
that CXCL8 and CXCL1 gene silencing in HTOXAR3 led to a 35% and a 20% decrease in OXA IC50 value as 
compared to siNTC cells, respectively (Fig. 7a,b).
Figure 4. Effect of Curcumin on constitutive and OXA-induced NF-κB activation. (a) Western blot images 
of phosphorylated p65 (p-p65 Ser536), total p65, Survivin and Bcl-2 in HT29 and HTOXAR3 cells after a  
24-hour treatment with 10 and 20 μM Curcumin (CURC). (b) Representative western blot images showing 
protein expression changes as indicated, in HT29 and HTOXAR3 cells after 24 h treatment with OXA 
or concomitant OXA plus Curcumin, for 0 to 120 minutes or 24 hours (c,d) Western blots showing p65 
protein expression in cytoplasmic and nuclear extracts of HT29 cells after treatment with OXA (10 μM) or 
OXA + Curcumin (10 μM each) for short-time exposure (0 to 30 min) or 24 h (e). TNFα was used as positive 
control at 50 ng/ml. Msh2 and α -tubulin were used as nuclear- and cytoplasmic-specific protein controls, 
respectively. Images are representative of at least 3 independent experiments. NT: Non-treated cells.
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CXCL8 and CXCL1 have been reported to act as autocrine growth factors through the induction of NF-κ B 
transcriptional activity10,36–38. Thus, we investigated NF-κ B activation by western blot under CXCL8 and CXCL1 
gene silencing conditions. As expected, phosphorylated Iκ Bα and Bcl-2 and Survivin protein expression levels 
were decreased in siCXCL8 and siCXCL1 cells as compared with siNTC cells. We also observed a decrease in Akt 
phosphorylation after silencing of both genes (Fig. 7c,d).
Globally, our results support first, the probable role of CXCL8 and CXCL1 chemokines in the OXA resistance 
acquisition process through the activation of the Akt/NF-κ B pathway and second, their implication in the syn-
ergism and greater efficacy of OXA plus Curcumin treatment in OXA-resistant cells. Accordingly, the expression 
levels of CXCL8 and CXCL1 could be used as predictive markers of this combination’s effectiveness.
Evaluation of CXCL8 and CXCL1 as predictive markers of OXA plus Curcumin treatment effec-
tiveness. In order to evaluate the potential of CXCL8 and CXCL1 as predictive biomarkers of OXA plus 
Figure 5. Gene expression patterns associated with OXA resistance and Curcumin + OXA synergism. 
(a) Hierarchical clustering of genes using pearson correlation as distance and average linkage with leaf order 
optimization. Cluster analysis was perfomed with TMEV version 4.8.1 using normalized expression values 
(mean subtracted log2 intensities divided by the standard deviation of the log2 intensities for each gene)  
(b) Table showing the top 10 up and down-regulated genes ranked by basal fold change between basal levels 
between HTOXAR3 and HT29 with regulation reversed by concomitant treatment.
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Curcumin treatment response, we analysed gene expression of both chemokines in a panel of 8 FFPE sam-
ples from explant cultures of CRC patients-derived liver metastases, that were treated with OXA or OXA plus 
Curcumin or vehicle (DMSO) for 24 h. Response to each treatment was assessed by means of decreasing prolif-
eration and/or apoptosis activation as indicated by ki-67 and cleaved caspase-3 inmunohistochemistry stain-
ing, respectively34. The RNA concentrations obtained from these samples ranged (20–75 ng/μL) and under our 
qRT-PCR conditions we were unable to detect CXCL8 expression. According to our in vitro results, we observed 
an increase of CXCL1 expression in 6/8 explants treated with OXA that was attenuated by the addition of 
Curcumin in 5/6 explants (Fig. 8a,b). We then studied the expression patterns of CXCL1 according to “response” 
to treatment. To do this, we assigned each case a score according to changes in ki-67 and cleaved caspase 3 stain-
ing after treatments (compared to vehicle). Thus, a score of 2 meant that ki-67 decreased and cleaved caspase 3 
Figure 6. CXCL1, CXCL8 and CXCL2 gene expression and CXCL1 and CXCL8 secreted protein levels 
after treatment with OXA, Curcumin or both. (a) Bar graphs illustrating relative gene expression levels 
(mean ± SEM) of the indicated chemokines in non-treated (NT) and after OXA or OXA plus Curcumin 
(CURC) treatment at IC50 doses in HT29 and HTOXAR3 cells. Gene expression levels of β -actin were used as 
endogenous control. *p-value < 0.05 relative to NT, #p-value < 0.05; ##p-value < 0.01, relative to HT29.  
◆ p-value < 0.05 relative to OXA. (b) Changes in chemokines’ gene expression after treatment with Curcumin 
at indicated doses. (c) Graph bars showing levels of secreted chemokines (mean ± SEM) measured by enzyme-
linked immunosorbent assay (ELISA) in the supernatants of treated cells as indicated. *p-value < 0.05; 
**p-value < 0.01; ***p-value < 0.001 relative to NT. ## p-value < 0.01, ###p-value < 0,001 relative to OXA. Results 
were obtained from at least 3 independent experiments.
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increased significantly after treatment; score 1 meant that ki-67 decreased or cleaved caspase 3 increased and 
score 0 meant that neither of them was changed according to this criteria. Interestingly, other authors have used 
a similar approach before39. As shown in Fig. 8c, explants p93 and p141 were the only ones with a score = 2 
when treated with Curcumin + OXA and interestingly, they had the highest CXCL1 basal levels as compared to 
explants with score 1 or 0. Although these results were obtained in a very few cases, they are in agreement with 
those obtained in vitro supporting the idea that those patients whose tumours present high CXCL1 levels (basally 
or after treatment with OXA-based chemotherapy) would be suitable candidates to be treated with a combination 
of Curcumin plus OXA (Fig. 8d). Whether this also applies to CXCL8, remains to be elucidated. Further clinical 
studies are on going in order to investigate these hypotheses.
Discussion
Chemotherapy schedules based on OXA combinations are essential in the clinical management of metastatic 
CRC patients. However, resistance phenomena remain one of the principal problems hindering treatment suc-
cess. In previous work we found that the deregulation of the NF-κ B signalling pathway could be an important 
mechanism of OXA-resistance acquisition in our in vitro models12. The role of elevated NF-κ B activity in the 
resistance of CRC cells to OXA-induced cell death was previously demonstrated30 and in agreement with other 
studies40, results presented here indicate that NF-κ B is constitutively active in all the CRC cell lines examined; 
however, we found that those cell lines with acquired resistance to OXA exhibited an increased activation of this 
pathway as compared to their matched sensitive parental cells, especially the HTOXAR3 resistant model, sug-
gesting a role for NF-κ B and its downstream targets in the development of the drug-resistant phenotype. This 
fact was reported to be associated with the acquisition of a mesenchymal phenotype along the OXA-resistance 
acquisition process41,42 and according to this, our exploratory functional enrichment analysis revealed EMT as 
one of the top hallmarks in the list of genes that were up-regulated in HTOXAR3 cell line in comparison with 
Figure 7. Effect of CXCL8 and CXCL1 siRNA-mediated gene silencing on OXA cytotoxicity and NF-kB 
signalling pathway activation in HTOXR3 cells. (a) Dose-response curves for HTOXAR3 cell line, after 
CXCL8 and (b) CXCL1 gene silencing, treated with 0-100 μM OXA for 24 hours (mean ± SEM). Insets show 
siRNA-mediated gene silencing efficiency at 48 h post-transfection. IC50 values are indicated as mean (95% CI). 
(c) Representative western blot images showing changes in phosphorylated Iκ Bα (p-Iκ Bα Ser32/36), 
phosphorylated Akt (p-Akt Ser473), Survivin, Bcl-2 and Cyclin D1 protein expression in HTOXAR3 cells under 
control (siNTC) and CXCL8 (siCXCL8) or (d) CXCL1 (siCXCL1) gene silencing. All results were obtained from 
at least 3 independent experiments.
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HT29 cells (Supplementary Table S3). Therefore our results could be explained in part by an EMT process in OXA 
resistant cells.
Similarly to other conventional anticancer drugs43,44, administration of OXA further potentiates NF-κ B activ-
ity, increasing transcriptional regulation and expression of anti-apoptotic genes10. Consistent with this, our results 
indicate that OXA activates NF-κ B in HT29 and HTOXAR3 cell lines through the classical pathway: Iκ Bα and 
p65 phosphorylation, p65 nuclear translocation and expression of NF-κ B-regulated genes, including Bcl-2 and 
Survivin. However, in agreement with other authors, we did not observe Iκ Bα degradation after OXA exposure. 
It seems that HT29 cells display a NF-κ B-dependent inflammatory response with final induction of target genes 
expression but at the same time, they are unable to degrade Iκ Bα , probably because of a defective proteasome 
system or by low levels of IKK activation31,45,46. Importantly, we observed that NF-κ B activation occurred very 
rapidly after OXA treatment, probably through the activation of death receptors, such as TNFR family47, but it 
was significantly sustained after treatment for 24 h only in the parental-sensitive HT29 cell line. This activation 
after OXA treatment could be due to the well-known capacity of OXA to induce both oxidative cellular stress and 
DNA damage. Differences observed between both cell lines could be explained by the tolerability of HTOXAR3 
to this damage; this would be reinforced by the fact that most of the DNA repair genes found to be differentially 
expressed in our microarray experiments between sensitive and resistant cells, were overexpressed in the latter 
(17/25) while expression of genes encoding for DNA damage response proteins, were down-regulated in this 
cell line indicating an adaptation to DNA damage and in consequence contributing to an attenuated NF-κ B 
activation after OXA treatment (Supplementary Table S4). We also observed a drastic reduction in Cyclin D1 
protein levels after OXA treatment. Cyclin D1 regulates the G1 to S phase transition, being synthesized during 
Figure 8. CXCL1 gene expression in explant cultures of patient-derived tissues after treatment with OXA 
or OXA + Curcumin. (a) Bar graph illustrating CXCL1 expression levels in 8 FFPE samples from explant 
cultures of CRC patients-derived liver metastases, that were treated with DMSO (NT), OXA or OXA plus 
Curcumin (CURC) for 24 h. (b) Scattergram reporting the expression levels of CXCL1 in NT, OXA or OXA 
plus Curcumin treated tissue explants. Horizontal lines represent mean values. (c) Table showing significative 
(S) or not significative (NS) changes in ki-67 (green) and cleaved caspase 3 (C3, blue) staining. Score 2 meant 
that ki-67 decreased and cleaved caspase increased significantly after the indicated treatment; score 1 meant 
that ki-67 decreased or cleaved caspase increased and score 0 meant that neither of them was changed. CXCL1 
gene expression changes after NT, OXA or OXA + Curcumin treatment are also shown. (d) Scatter plot showing 
CXCL1 expression according to score values. Horizontal lines represent mean values. *p-value < 0.05 relative to 
NT (Wilcoxon test).
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the G1 phase and degraded as the cell enters the S phase48. As other authors and we have reported, a 24-h OXA 
treatment causes S-phase accumulation in HT29 cells49,50; this effect could explain the Cyclin D1 protein decrease 
after this time of OXA treatment. Targeting of NF-κ B has been explored extensively as a therapeutic strategy 
against cancer and Curcumin has been demonstrated to suppress NF-κ B activation and NF-κ B-dependent gene 
expression6. As expected, we found that Curcumin suppressed constitutive and OXA-induced NF-κ B activation 
as well as proliferation13,21 and it was able to sensitize CRC cells to OXA treatment. Indeed, the concomitant 
treatment of Curcumin and OXA led to a significant suppression of cell proliferation and colony formation as 
compared to either treatment alone in LoVo and HT29 cells. The combination was especially efficacious in their 
corresponding OXA-resistant derived LoVOXAR3 and HTOXAR3 cells. This observation was also reported by 
Howells et al.19. Drug combination experiments revealed that the concomitant treatment was more synergistic 
in the HTOXAR3 cell line than in the HT29 cell line and in fact, this treatment reverted the resistance to OXA in 
the former. However, under the same conditions, no synergism was found between the two drugs in the LoVo/
LoVOXAR3 pair. These differences could be partly explained by differences of genetic features between the two 
in vitro models, by the fact that the NF-κ B pathway was not so evidently hyperactivated in LoVOXAR3 cells or 
by the necessity to test specific combination schedules in these cell lines in order to find the most synergistic one 
in this model. We found this effect was not associated with an increase in cell death after 24 h treatment which 
was in line with other studies50. Taken together, these results are of paramount interest because they suggest that 
a suboptimal concentration of OXA could be used in combination with Curcumin leading to similar efficacy but 
minimizing toxicity.
We then wanted to know whether a specific gene expression pattern in the HTOXAR3 cell line was associated 
with the greater efficacy of OXA plus Curcumin. Three NF-κ B-transcriptionally regulated CXC-chemokines, 
CXCL8, CXCL1 and CXCL2, were highly overexpressed as a result of OXA-resistance acquisition in the HTOXAR3 
cell line and at the same time were specifically down-regulated after treatment with OXA plus Curcumin in these 
cells. These pro-inflammatory chemokines play an important role in regulating CRC progression, angiogene-
sis and metastasis51, processes that have been associated with OXA resistance42. The effect of chemotherapy on 
CXCL852,53, CXCL1 and CXCL254 gene transcription has been described elsewhere. For example, Wilson et al. 
showed that OXA treatment induced CXCL8 and CXCL1 gene expression and potentiated NF-κ B activation10. 
Similarly, we show that OXA treatment strongly induced CXCL8 and CXCL1 gene and protein expression only 
in the HT29 OXA-sensitive cells, which was in agreement with results of NF-κ B activation after 24 h of treatment 
with OXA only in this cell line. Curcumin has been demonstrated to down-regulate the expression of CXCL1 and 
CXCL855,56, interestingly the addition of Curcumin to OXA treatment suppressed these chemokines’ expression 
only in the OXA-resistant HTOXAR3 cell line. In summary, this finding suggests the implication of these two 
chemokines in the observed greater efficacy and synergism of OXA and Curcumin in the OXA-resistant cells. We 
further demonstrated that overexpression of CXCL8 and CXCL1 is indeed affecting OXA-resistance acquisition 
since their gene silencing led to a significant although slight sensitization of HTOXAR3 cells.
CXCL8 and CXCL1 can be secreted and promote positive autocrine and/or paracrine feedback loops through 
their binding to the CXC receptors CXCR1 and CXCR2 which in turn activates the NF-κ B signalling path-
way10. We show that this also happened in our model as CXCL8 and CXCL1 gene silencing was associated with 
decreased phosphorylation of Iκ Bα and reduced protein levels of Bcl-2 and Survivin in HTOXAR3 cells. Under 
these conditions we also observed a decrease in Akt phosphorylation, which suggests that at least in part, the 
observed NF-κ B hyperactivation in the resistant cell line could be a result of an acquired increased activation of 
Akt. These results are supported by prior studies indicating that overexpression of CXCL8 causes phosphoryla-
tion of Akt and NF-κ B activation in the HCT116 CRC cell line57. This signalling pathway has been associated 
with resistance to OXA in prostate cancer cells10 and treatment with a CXCR2 antagonist such as SCH-527123, 
sensitizes cells to OXA in preclinical colon cancer models58. We propose that not only the inhibition of NF-κ B 
per se, but also the binding of chemokines to receptors that activate this pathway could be useful strategies in 
increasing the efficacy of OXA in CRC. Finally, we tried to translate our results to the clinical setting. Facing the 
impossibility of finding samples from patients treated with Curcumin, we took advantage of previous work from 
our collaborators in which they utilised patient-derived colorectal liver metastases explant cultures treated with 
different schedules containing Curcumin34. In order to mimic our in vitro experiments, we chose those explants 
that were treated with OXA or OXA + Curcumin. We found that, treatment with OXA also induced the expres-
sion of CXCL1 that was repressed by the addition of Curcumin. Interestingly, the explants with best “response” 
to OXA + Curcumin, were those with the highest basal levels of CXCL1, suggesting that this chemokine could be 
a good predictive marker for this treatment. These results are not definitive yet they lead us to hypothesize that 
i) in some cases, the addition of Curcumin to OXA could lead to a more efficacious treatment, permitting dose 
reduction of the latter and avoiding toxicity; ii) combinations of Curcumin + OXA could be an effective treatment 
in metastatic CRC patients, including those that had progressed to an OXA-based first line. In this case, we have 
to be careful and take into account that those patients developing toxicity to the first-line treatment would not 
be candidates to a second-line with OXA and iii) the measurement of CXCL1 (and probably CXCL8) in tumours 
(but also in serum) could serve to identify those patients that are more likely to respond to OXA + Curcumin. 
Clinical trials such as the one that is being coordinated by the Howells’ group in Leicester (NCT01490996; www.
ClinicalTrials.gov) are warranted in order to validate these results and to establish the best conditions to include 
this compound in the clinical management of CRC patients.
Materials and Methods
Cell lines. Human tumor-derived colorectal adenocarcinoma HT29, LoVo, and DLD1 cell lines (American 
Type Culture Collection) were used as the parental cells to obtain the oxaliplatin-resistant sublines HTOXAR3, 
LoVOXAR3 and DLDOXAR3, respectively as a result of continuous exposure to increasing doses of OXA as 
described previously12. Cell lines were grown as monolayer in RPMI 1640 (Invitrogen, Life Technologies) medium 
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(DLD1 and DLDOXAR3) and DMEM (Invitrogen, Life Technologies) medium (HT29 and HTOXAR3) supple-
mented with 10% of heat-inactivated FCS (Reactiva), 400 units/mL penicillin, 40 μg/mL gentamicin, 2 mmol/L 
L-glutamine (Sigma), and 10 mmol/L HEPES (Sigma). LoVo and LoVOXAR3 cells were grown in Ham’s F-12 
(Invitrogen, Life Technologies) with 20% FCS (Reactiva), 200 units/mL penicillin, and 20 μg/mL gentamicin.
All cell lines were cultured at 37 °C in a humidified atmosphere of 5% CO2. Cells were periodically tested for 
Mycoplasma contamination and were authenticated by short tandem repeat profiling.
Samples from explant cultures of patient-derived tissues. FFPE explant cultures were a gift of Dr. 
Lynne Howells (University of Leicester). Procedures for their obtaining, culture, treatment and response evalu-
ation are described in34. These samples were obtained from tumours from patients undergoing surgical resec-
tion for colorectal liver metastases at University Hospitals of Leicester NHS Trust. Ethical approval for this fully 
anonymised, excess tissue study was granted by Leicestershire, Northamptonshire and Rutland Ethics Committee 
(REC reference 09/H0402/45). Additionally, the Clinical Research Ethical Committee from Hospital Germans 
Trias i Pujol provided approval for the study.
Drugs. OXA and Curcumin (Sigma) were prepared in water and in absolute ethanol respectively at a con-
centration of 10 mM and stored at − 20 °C. Further dilutions of each drug were made in culture medium to final 
concentrations before use.
Western blot analysis. Cells were homogenized in RIPA plus buffer [Phosphate Buffered Saline (PBS); 
NP-40 1%; Na deoxycholate 0.5%; SDS 0.1%; EDTA 1 mM; NaF 50 mM; NaVO3 5 mM] containing a cocktail 
of EDTA-free protease inhibitors (Roche). Protein concentration was determined by the Bradford method by 
using the DC™ Protein Assay (Bio-Rad) and bovine serum albumin as a standard. Fifty micrograms of protein 
were loaded and subjected to electrophoresis in 10% SDS-PAGE gels (Invitrogen, Life Technologies) and trans-
ferred onto PVDF membranes (Bio-Rad). After 1 h of blocking (LICOR Biosciences) membranes were incubated 
overnight at 4 °C using specific primary antibodies against phospho-p65 Ser536 (Merck-Millipore, 1:2000), p65 
(Cell Signaling, 1:1000), phospho-Iκ Bα Ser32/36 (Cell Signaling 1:1000), Iκ Bα (Abcam, 1:1000) Bcl-2 (Abcam, 
1:1000), Cyclin D1 (Abcam, 1:1000), Survivin (Abcam, 1:1000), phospho-Akt (Cell Signaling, 1:1000) and Akt 
(Cell Signaling, 1:1000). Mouse monoclonal anti-α -tubulin antibody (Sigma Aldrich, 1:20000) was used as inter-
nal and cytoplasmatic control. Anti-Msh2 antibody (Calbiochem, 1:500) was used as nuclear protein control. 
Membranes were incubated with IRDye rabbit and mouse secondary antibodies (1:10000) (LICOR Biosciences) 
for 50 minutes protected from the light. Membranes were scanned by using an Odyssey Imaging System and ana-
lyzed with Odyssey v2.0 software (LICOR Biosciences).
Preparation of nuclear extracts. The nuclear extracts were prepared according to Schreiber et al.59. 
Briefly, cells were washed with cold PBS and suspended in 0.4 ml hypotonic lysis buffer containing protease inhib-
itors and 0.5% Nonidet P-40 for 30 minutes. The homogenate was centrifuged, and supernatant containing the 
cytoplasmic extracts was stored frozen at − 80 °C. The nuclear pellet was washed twice with lysis buffer and then 
resuspended in 50 μl ice-cold nuclear extraction buffer. After 30 minutes of intermittent mixing, the extract was 
centrifuged, and supernatants containing nuclear extracts were secured. The protein content was measured by the 
Bradford method by using the DC™ Protein Assay (Bio-Rad).
Cell viability Assay. The cytotoxicity of OXA, Curcumin and combination of both was assessed by the 3-(4, 
5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) test (Roche Diagnostics). Cells were seeded 
in 96-well microtiter plates (Nunc) at a density of 1,500 (HT29 and HTOXAR3), 3,000 cells/well (LoVo and 
LoVOXAR3) and 4,000 cells/well (DLD1 and DLDOXAR3). Cells were treated with different drug concentrations 
for 24 h. Subsequently, the drug was removed and fresh media was added to each well. Cells were allowed to grow 
for 72 h. MTT was then added and doses for each fraction of survival (ranging from 10% to 90% of cell viability) 
were determined in each cell line by the median-effect line method. The maximum concentration of absolute 
ethanol (Curcumin vehicle) used was 0,3% which did not affect cell proliferation in our experiments.
Analysis of combined drug effects. Cell viability was assessed by MTT assay, as described above, and 
data were analyzed by Chou and Talalay method60. The analysis of combined drug effects was performed in each 
experiment with serial dilution of both drugs administered at doses that typically correspond to 1/8, 1/4, 1/2, 
5/8, 3/4, 7/8, 1, 1.5 and 3 of the individual IC50 values. Fractional survival was then calculated by dividing the 
number of cells in drug-treated plates by the number of cells in control plates. Data was subsequently analyzed 
by the method of Chou and Talalay. For each level of cytotoxicity, a parameter called combination index (CI) was 
then calculated according to the following equation: Cif = D1/(Df)1 + D2/(Df)2 + α ·D1·D2/(Df)1·(Df)2; where 
(D1) and (D2) are the concentrations of the combination required to produce survival f; (Df)1 and (Df)2 are the 
concentrations of the individual drugs required to produce f, and α = 1 or 0 depending on whether the drugs are 
assumed to be mutually nonexclusive or mutually exclusive, respectively, in their action. For Curcumin and OXA 
combination we considered an α = 1 since they have a mutually exclusive mechanism of action. According tot 
this method, synergism is indicated by CI < 1, antagonism by a CI > 1, and additivity by CI = 1.
Colony-formation assay. Colony-formation assays were also performed to evaluate the cytotoxicity of 
OXA, Curcumin and their combination. Briefly, cells were plated in 6-well plates at a density of 300 cells/well 
(HT29 and HTOXAR3) or 500 cells/well (LoVo and LoVOXAR3) and allowed to attach. The next day, different 
dilutions of the corresponding drugs were added for 24 h. After exposure, cells were washed in PBS and cultured 
in free media until colonies were formed (10 days). Cells were subsequently washed, fixed with a Methanol/acetic 
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acid (3:1) solution for 10 min and stained with a solution of crystal violet (0,5%) for 10 min. After staining, cells 
were thoroughly washed with PBS. Colonies were counted manually.
Gene silencing. Interfering RNA (siRNA) was used to generate specific knockdowns of CXCL8 and CXCL1 
in the HTOXAR3 cell line. Cells were seeded at 60% confluence in serum and antibiotic-free OptiMem medium 
(Invitrogen, Life Technologies) in 6-well plates. CXCL8 and CXCL1 were transiently silenced by using a pool of 4 
different siRNAs (Smartpool On-target plus: CXCL8 siRNA, #L-004756; CXCL1 siRNA, #L-003898 ;Dhamacon, 
GE, respectively). As a transfection agent we used Lipofectamine RNAiMAX (Invitrogen, Life Technologies) 
according to the manufacturer’s instructions. A silencer negative transcription control (Cat No. AM4611; 
Ambion) was introduced in each experiment. Following 24 h of transfection, medium was replaced with full 
DMEM medium supplemented with serum and antibiotic. Validation of CXCL8 and CXCL1 knockdown was 
assessed by qRT-PCR. In fine-tuning experiments, non-transfected cells (Mock) were introduced to ensure that 
transfection had minimal effects on gene expression, proliferation and cell viability.
Quantitative RT-PCR. Gene expression experiments were performed as described in previous work12. 
Retrotranscription was performed with MMLV reverse transcriptase (Invitrogen, Life Technologies) in accord-
ance to the manufacturer’s instructions. Then, 2 μL of each RT reaction was amplified in a LightCycler® 480 PCR 
system (Roche), using the KAPA SYBR Fast Master Mix (KAPA Biosystems, Woburn, MA, USA). Primer pairs 
used are listed in Supplementary Table S1. The PCR product size generated with these primers was 155 bp for 
CXCL8, 104 bp for CXCL1 and 113 bp for CXCL2. Relative gene expression quantification was calculated accord-
ing to the comparative Ct method as described elsewhere using β -Actin (Applied Biosystems) as endogenous 
control. In all experiments, only triplicates with a Ct value lower than 0.20 SD were accepted. In addition, for each 
sample analyzed, a retrotranscriptase minus control was run in the same plate to ensure absence of genomic DNA 
contamination.
ELISA assay. Culture supernatants were collected 24 h post-treatment with OXA, Curcumin or their com-
bination. CXCL8 and CXCL1 secretion was measured with the IL-8 OptEIA ELISA Set (Becton Dickinson) and 
the RayBio Human GRO-alpha ELISA kit (RayBiotech), respectively; following the manufacturer’s instructions.
Propidium iodide test. OXA and Curcumin-induced cell death was measured by using Propidium Iodide 
(PI). After 24, 48 and 72 h of treatment with OXA, Curcumin or the combination of both, cells were harvested 
with Accutase (ref. A11105-01, Invitrogen) and resuspended in cold PBS with a PI concentration of 3 μM. The PI 
fluorescence was determined on a FACSCanto II flow cytometer (Becton Dickinson Immunocytometry System).
Immunofluorescence analysis. Subcellular localization of p65 (NF-κ B) was detected by immunofluores-
cence, as described in previous work49.
Microarray gene expression profiling. We used Agilent HumanV2 Microarrays for global gene expres-
sion profiling. 100 ng of total RNA was used as input for reverse transcription. cRNA was then fluorescently 
tagged with Cy3-CTP nucleotide by in vitro transcription using the low input quick Amp Labeling kit followed 
by hybridization, washing, scanning and image extraction using commercial software; all steps were performed 
strictly following the manufacturer’s instructions (Agilent, Palo Alto, CA). Subsequent data pre-processing and 
analysis was as follows: raw data intensities were background corrected using normexp, and log2intensity dis-
tributions were made comparable between samples using quantile normalization. Differential gene expression 
was assessed by fitting to an empirical Bayesian linear model. Statistical significance in differential gene expres-
sion was determined by setting a false discovery rate applying the Benjamini and Yekutiely method for multi-
ple testing adjustment correction. For analysis we used the Limma package and the R statistical programming 
environment61.
We analyzed total RNA obtained from 3 biological replicates of 3 conditions: basal without treatment, OXA 
individual treatment and OXA plus Curcumin in 2 cell lines (HT29 and HTOXAR3). Data are publicly available 
and can be accessed with the GSE76092 identifier in the GEO database (http://www.ncbi.nlm.nih.gov/geo/).
To look for differentially expressed genes following desired patterns of gene expression we first applied a 
dual filter applying as cut-off an absolute fold change |FC| > 1.2 and a q-value < 0.05 on each specific compar-
ison. Then the intersection between lists was computed and Venn diagrams where plotted using Venny 2.02 
(http://bioinfogp.cnb.csic.es/tools/venny/index.html)
Functional enrichment analysis. To explore relevant enrichment in gene ontology categories within the 
genes found in the intersection between significantly regulated gene list, we used GOrilla web server tool62,63. 
For independent confirmation we also used the GSEA64 gene set investigation tool (http://software.broadin-
stitute.org/gsea/msigdb/annotate.jsp) and computed significant overlaps with GO ‘C5’ molecular function 
‘MF’ gene sets as well as the ‘H’ gene set collection (hallmarks, a collection of 50 sets representing specific well 
defined biological states or processes identified by extracting coherent representatives from gene set overlaps 
in the version available November 20 2015 http://www.broadinstitute.org/cancer/software/gsea/wiki/index.php/
MSigDB_v5.0_Release_Notes)
Statistical analysis. Data are presented as mean ± SEM of at least 3 independent experiments and the statis-
tical analysis was performed with Graphpad Prism V.4 software. Statistical differences between IC50 were deter-
mined by graphic representation of dose-response curves and subsequent non-linear regression analysis and 
F-test. Comparisons among different experimental conditions were carried out through the T-student or two-way 
ANOVA test followed by Bonferroni post-test. Values of p ≤ 0.05 were considered significant.
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